Develops personalized immunotherapies for the treatment of cancer. Focuses on leveraging the patient's own immune system to fight cancer. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The company sells $1.9M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $40.6M against $1.9M in annual sales.
The stock sits at $0.27. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown, the price history.